Philips Electronics has agreed to pay $5.1 billion or $66 per share of Respironics. Respironics provides treatment for sleep disorders which are estimated to affect 6% of the population in the U.S. Philips home healthcare division has made a number of acquisition this year and now care about one million people through various services in the U.S. |
More:
